Post-exertional malaise (PEM), sometimes referred to as post-exertional symptom exacerbation (PESE)[1] or post-exertional neuroimmune exhaustion (PENE),[2] is a worsening of symptoms that occurs after minimal exertion. It is the hallmark symptom of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and common in long COVID and fibromyalgia[3][1] PEM is often severe enough to be disabling, and is triggered by ordinary activities that healthy people tolerate. Typically, it begins 12–48 hours after the activity that triggers it, and lasts for days, but this is highly variable and may persist much longer.[4][5][6] Management of PEM is symptom-based, and patients are recommended to pace their activities to avoid triggering PEM.

Post-exertional malaise
Other namesPost-exertional symptom exacerbation (PESE)
Postexertional malaise (PEM)
Post-exertional neuroimmune exhaustion (PENE)
Diagram with examples of cognitive, physical, and emotional activities that may trigger PEM
Chart of physical, cognitive, and emotional activities that may trigger PEM
SymptomsWorsening of symptoms after ordinary activity
CausesChronic fatigue syndrome
Long COVID
TreatmentSymptomatic

History edit

One of the first definitions of ME/CFS, the Holmes Criteria published in 1988, does not use the term post-exertional malaise but describes prolonged fatigue after exercise as a symptom.[7] The term was later used in a 1991 review summarizing the symptoms of ME/CFS. Afterwards, the Canadian Consensus Criteria from 2003[8] and the International Consensus Criteria from 2011[9] used the term, as well as later definitions.

Description edit

 
Typical timeframes of post-exertional malaise after normal daily activities, 2020
 
Severe symptoms triggered by a 2-day CPET in people with ME/CFS, 2023

Post-exertional malaise involves an exacerbation of symptoms, or the appearance of new symptoms, which are often severe enough to impact a person's functioning.[10] While fatigue is often prominent, it is "more than fatigue following a stressor".[6] Other symptoms that may occur during PEM include cognitive impairment, flu-like symptoms, pain, weakness, and trouble sleeping.[6][4] Though typically cast as a worsening of existing symptoms, patients may experience some symptoms exclusively during PEM.[6] Patients often describe PEM as a "crash", "relapse", or "setback".[6]

PEM is triggered by "minimal"[5] physical or mental activities that were previously tolerated, and that healthy people tolerate, like attending a social event, grocery shopping, or even taking a shower.[4] Sensory overload,[10] emotional distress, injury, sleep deprivation, infections, and spending too long standing or sitting up are other potential triggers.[6] The resulting symptoms are disproportionate to the triggering activity and are often debilitating, potentially rendering someone housebound or bedbound until they recover.[11][6][12][4]

The course of a crash is highly variable. Symptoms typically begin 12–48 hours after the triggering activity,[5] but may be immediate, or delayed up to 7 days.[6] PEM lasts "usually a day or longer",[11] but can span hours, days, weeks, or months.[6] The level of activity that triggers PEM, as well as the symptoms, vary from person to person, and within individuals over time.[6] Due to this variability, affected people may be unable to predict what will trigger it.[4] This variable, relapsing-remitting pattern can cause one's abilities to fluctuate from one day to the next.[1]

Diagnosis edit

PEM is a hallmark symptom of ME/CFS and is common in long COVID.[13][14][15]

However, its presence can be difficult to assess because patients and doctors may be unfamiliar with it.[1][14] Hence, the WHO recommends that clinicians explicitly ask long COVID patients whether symptoms worsen with activity.[1]

The 2-day Cardiopulmonary Exercise Test (CPET) may aid in documenting PEM, showing apparent abnormalities in the body's response to exercise.[16] Still, more research on developing a diagnostic test is needed.

Epidemiology edit

PEM is considered a cardinal symptom of ME/CFS by modern diagnostic criteria: the International Consensus Criteria,[4][11] the National Academy of Medicine criteria,[17][18] and NICE's definition of ME/CFS[12] all require it. The Canadian Consensus Criteria require "post exertional malaise and/or [post exertional] fatigue" instead.[19][20][21][17][22] On the other hand, the older Oxford Criteria lack any mention of PEM,[23] and the Fukuda Criteria consider it optional. Depending on the definition of ME/CFS used, PEM is present in 60 to 100% of ME/CFS patients.[6]

A majority of people with long COVID experience post-exertional malaise as well.[14]

Management edit

There is no treatment or cure for PEM. Pacing, a management strategy in which someone plans their activities to stay within their limits, may help avoid triggering PEM.[24]

Physical therapy for people with long COVID must be modified to avoid triggering PEM in susceptible patients.[25]

References edit

  1. ^ a b c d e Clinical management of COVID-19 Living Guideline. World Health Organization. January 13, 2023. pp. 113–4. Archived from the original on May 22, 2023. Retrieved January 14, 2023.
  2. ^ Twisk F (December 20, 2018). "Myalgic Encephalomyelitis or What? The International Consensus Criteria". Diagnostics. 9 (1): 1. doi:10.3390/diagnostics9010001. ISSN 2075-4418. PMC 6468846. PMID 30577429.
  3. ^ Barhorst EE, Boruch AE, Cook DB, Lindheimer JB (2022). "Pain-Related Post-Exertional Malaise in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) and Fibromyalgia: A Systematic Review and Three-Level Meta-Analysis". Pain Medicine. 23 (6): 1144–1157. doi:10.1093/pm/pnab308. PMID 34668532. Archived from the original on May 21, 2023. Retrieved February 11, 2024.
  4. ^ a b c d e f "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Symptoms". Centers for Disease Control and Prevention. U.S. Department of Health & Human Services. July 14, 2017. Archived from the original on August 22, 2020. Retrieved September 23, 2017.
  5. ^ a b c "Terms: Post-exertional malaise". Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management - Recommendations. NICE (Report). October 29, 2021. NICE guideline NG206. Archived from the original on December 29, 2021. Retrieved May 12, 2022.
  6. ^ a b c d e f g h i j k "Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness" (PDF). National Academy of Medicine. 2015. pp. 78–86. Archived (PDF) from the original on January 20, 2017. Retrieved May 12, 2022.
  7. ^ Holmes GP (March 1, 1988). "Chronic Fatigue Syndrome: A Working Case Definition". Annals of Internal Medicine. 108 (3): 387–389. doi:10.7326/0003-4819-108-3-387. ISSN 0003-4819. PMID 2829679.
  8. ^ Carruthers BM, Jain AK, De Meirleir KL, Peterson DL, Klimas NG, Lerner AM, et al. (January 2003). "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols". Journal of Chronic Fatigue Syndrome. 11 (1): 7–115. doi:10.1300/J092v11n01_02. ISSN 1057-3321.
  9. ^ Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. (October 2011). "Myalgic encephalomyelitis: International Consensus Criteria". Journal of Internal Medicine. 270 (4): 327–338. doi:10.1111/j.1365-2796.2011.02428.x. ISSN 0954-6820. PMC 3427890. PMID 21777306.
  10. ^ a b Grach SL, Seltzer J, Chon TY, Ganesh R (October 2023). "Diagnosis and Management of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". Mayo Clinic Proceedings. 98 (10): 1544–1551. doi:10.1016/j.mayocp.2023.07.032. PMID 37793728. S2CID 263665180.
  11. ^ a b c Carruthers BM, van de Sande MI, De Meirleir KL, Klimas NG, Broderick G, Mitchell T, et al. (October 2011). "Myalgic encephalomyelitis: International Consensus Criteria". Journal of Internal Medicine. 270 (4): 327–338. doi:10.1111/j.1365-2796.2011.02428.x. PMC 3427890. PMID 21777306.
  12. ^ a b "1.2 Suspecting ME/CFS". Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management – Recommendations. NICE (Report). October 29, 2021. NICE guideline NG206. Archived from the original on December 29, 2021. Retrieved May 12, 2022.
  13. ^ "Information for Healthcare Providers | ME/CFS | CDC". www.cdc.gov. November 11, 2022. Archived from the original on August 9, 2020. Retrieved June 7, 2023.
  14. ^ a b c Davis HE, McCorkell L, Vogel JM, Topol EJ (January 13, 2023). "Long COVID: major findings, mechanisms and recommendations". Nature Reviews Microbiology. 21 (3): 133–146. doi:10.1038/s41579-022-00846-2. ISSN 1740-1534. PMC 9839201. PMID 36639608.
  15. ^ "Long COVID or Post-COVID Conditions". Centers for Disease Control and Prevention. September 1, 2022. Archived from the original on January 14, 2022. Retrieved July 3, 2022.
  16. ^ Eun-Jin L, Eun-Bum K, Eun-Su J, Chang-Gue S (2020). "The Prospects of the Two-Day Cardiopulmonary Exercise Test (CPET) in ME/CFS Patients: A Meta-Analysis". Journal of Clinical Medicine. 9 (12). J Clin Med.: 4040. doi:10.3390/jcm9124040. PMC 7765094. PMID 33327624.
  17. ^ a b "IOM 2015 Diagnostic Criteria | Diagnosis | Healthcare Providers | Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) | CDC". www.cdc.gov. November 8, 2018. Archived from the original on March 8, 2019. Retrieved March 8, 2019.
  18. ^ "Symptoms of ME/CFS | Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)". CDC. January 27, 2021. Archived from the original on August 22, 2020. Retrieved September 23, 2017.
  19. ^ Myhill S, Booth NE, McLaren-Howard J (2009). "Chronic fatigue syndrome and mitochondrial dysfunction" (PDF). Int J Clin Exp Med. 2 (1): 1–16. PMC 2680051. PMID 19436827. Archived (PDF) from the original on July 11, 2019. Retrieved March 8, 2019.
  20. ^ Carruthers BM, van de Sande MI (2005). "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Clinical Case Definition and Guidelines for Medical Practitioners" (PDF). sacfs.asn.au. p. 8. Archived (PDF) from the original on March 4, 2019. Retrieved March 8, 2019. There is an inappropriate loss of physical and mental stamina, rapid muscular and cognitive fatigability, post exertional malaise and/or fatigue and/or pain and a tendency for other associated symptoms within the patient's cluster of symptoms to worsen.
  21. ^ "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Key Facts" (PDF). nap.edu. 2015. p. 2. Archived (PDF) from the original on March 27, 2019. Retrieved March 8, 2019.
  22. ^ Wright Clayton E, Alegria M, Bateman L, Chu L, Cleeland C, Davis R, et al. (2015). "Beyond Myalgic Encephalomyelits/Chronic Fatigue Syndrome: Redefining an Illness (Report Guide for Clinicians)" (PDF). nationalacademies.org. Nancy Klimas, A. Martin Lerner, Cynthia Mulrow, Benjamin Natelson, Peter Rowe, Michael Shelanski. National Academy of Medicine (Institutes of Medicine). p. 7. Archived (PDF) from the original on September 29, 2018. Retrieved March 8, 2019.
  23. ^ Sharpe M (February 1991). "A report--chronic fatigue syndrome: guidelines for research". Journal of the Royal Society of Medicine. 84 (2): 118–121. doi:10.1177/014107689108400224. PMC 1293107. PMID 1999813.
  24. ^ "1.11 Managing ME/CFS". Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management – Recommendations. NICE (Report). October 29, 2021. NICE guideline NG206. Archived from the original on December 29, 2021. Retrieved July 17, 2022.
  25. ^ Clinical management of COVID-19 Living Guideline. World Health Organization. January 13, 2023. p. 109. Archived from the original on May 22, 2023. Retrieved January 14, 2023.